2 results
Approved WMORecruiting
The primary objective is to investigate if IMO-2125 is capable of a) lowering the number of tumor positive SLN and b) inducing a loco-regional and systemic immune response. The secondary objective is to investigate RFS and OS at 18 months, 24 months…
Approved WMORecruiting
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.